Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1995-6-29
|
pubmed:abstractText |
We have studied the relationship between interleukin-8 (IL-8) and interleukin-1 alpha (IL-1 alpha) release after stimulation with all-trans retinoic acid (ATRA) and tumor necrosis factor-alpha (TNF-alpha) in the human epithelial ovarian cancer cell line HOC-7. Both IL-1 alpha and IL-8 protein release were enhanced by treatment with ATRA and TNF-alpha after 48 h exposure. Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells. Expression of IL-8 mRNA was enhanced by the individual stimuli, whereas co-treatment with IL-1ra resulted in a loss of IL-8 specific transcripts, except in TNF-alpha treated cells. Inhibition of de novo protein synthesis by cycloheximide (CHX) and simultaneous blocking of IL-1 alpha activity by IL-1ra for 24 h revealed that ATRA controls IL-8 gene expression transcriptionally and that the extent of IL-8 protein release can be markedly influenced by cellular expressed IL-1 alpha.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-8,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tretinoin,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0006-291X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
25
|
pubmed:volume |
210
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
898-906
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7763262-Adenocarcinoma,
pubmed-meshheading:7763262-Blotting, Northern,
pubmed-meshheading:7763262-Cell Line,
pubmed-meshheading:7763262-Dose-Response Relationship, Drug,
pubmed-meshheading:7763262-Female,
pubmed-meshheading:7763262-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:7763262-Humans,
pubmed-meshheading:7763262-Interleukin-1,
pubmed-meshheading:7763262-Interleukin-8,
pubmed-meshheading:7763262-Kinetics,
pubmed-meshheading:7763262-Ovarian Neoplasms,
pubmed-meshheading:7763262-RNA, Messenger,
pubmed-meshheading:7763262-Recombinant Proteins,
pubmed-meshheading:7763262-Transcription, Genetic,
pubmed-meshheading:7763262-Tretinoin,
pubmed-meshheading:7763262-Tumor Cells, Cultured,
pubmed-meshheading:7763262-Tumor Necrosis Factor-alpha
|
pubmed:year |
1995
|
pubmed:articleTitle |
Regulation of interleukin-8 gene expression by all-trans retinoic acid.
|
pubmed:affiliation |
Department of Internal Medicine I, University Hospital of Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|